Loading clinical trials...

Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma | Clinical Trials | Clareo Health

WITHDRAWNPHASE2

Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma

A Phase II Study of Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma

NCT03719898•Fox Chase Cancer Center

Summary

FDA approved drugs to treat patients with relapsed or refractory anaplastic large cell lymphoma (ALCL) has a median progression free survival of 20 months. Majority of patients relapse in 2 years. This study will evaluate overall response rate of next generation ALK inhibitor brigatinib in ALK positive ALCL patients by overcoming mechanisms of resistance to ALK inhibitors on cancer patients.

Detailed Description

Although patients with ALK+ anaplastic large cell lymphoma (ALCL), a type of peripheral T-cell lymphoma (PTCL), are considered to have a favorable prognosis, relapse is not uncommon if multiple International Prognostic Index (IPI) risk factors, age ≥ 40, and beta-2 microglobulin ≥ 3 mg/L are present at diagnosis. For patients older than 40 years at diagnosis and beta-2 microglobulin ≥ 3 mg/L, progression-free survival (PFS) and overall survival (OS) is less than 50% at 2.5 years when treated with standard anthracycline-based induction therapy. Patients with ALK+ ALCL with 3 or more IPI risk factors have a 5-year PFS rate of only 20% to 30%. In total, approximately 40 to 65% of patients with ALCL develop recurrent disease after front-line chemotherapy and at relapse, the disease is historically resistant to conventional chemotherapy. Current FDA approved for treatment of relapsed or refractory PTCLs have a median PFS of 20 months and majority of patients relapse within 2 years. Despite ALK tyrosine kinase being an attractive target for management of relapsed or refractory ALK+ ALCL, ALK gene rearrangement makes cancer resistant to first and 2nd generation ALK inhibitors. Brigatinib is a next generation inhibitor with broad activity aganst a broad spetrum of resistant ALK mutants. Brigatinib has been shown to overcome mechanisms associated with resistane to 1st and 2nd generation ALK inhibitors. It is approved as 2nd line of treament in non small cell lung cancer patients. and is being tested in patients with relapsed or refractory ALK-positive ALCL.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Patients must have a histologically confirmed diagnosis of relapsed or refractory ALCL with documented ALK+ status
•2. Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIL 2017 criteria as described in detail in section 11.0
•3. Ongoing toxicities from prior therapy must be resolved to ≤ grade 1 (with the exceptions of grade 2 peripheral neuropathy and/or alopecia). Patients with existing toxicities that are non-significant even though greater than grade 1 can be enrolled after discussion with the sponsor-investigator.
•4. Age \> 18 years.
•5. ECOG performance status 0-2
•6. Prior use of ALK inhibitors aside from brigatinib is permitted but 8 patients enrolled need to be ALK inhibitor treatment naive
•7. Patients with no archival tissue available must be agreeable to fresh biopsy at baseline.
•8. Patients with a known history of HIV are permitted provided the CD4 count ≥ 100 cells/µL and serum HIV viral load \< 50 copies/mL. Patients must be on stable combination antiretroviral therapy at the time of treatment initiation.
•9. Patients must have normal organ and marrow function as defined below
•* Absolute neutrophil count \> 1,000/mcL
+10 more criteria

Exclusion Criteria

•1. History of another active primary malignancy within 2 years of initiating study treatment with the exception of non-melanomatous skin cancer, or any cancer that in the judgment of the investigator has been treated with curative intent and will not interfere with the study treatment plan and response assessment.
•2. Patients who have received chemotherapy or radiation therapy within 2 weeks of initiating study treatment.
•3. Patients may not be receiving any other investigational agents.
•4. Patients who have symptomatic CNS metastases (parenchymal or leptomeningeal) at screening or asymptomatic disease requiring an increasing dose of corticosteroids to control symptoms within 7 days prior to randomization.
•Note: If a patient has worsening neurological symptoms or signs due to CNS metastasis, the patient needs to complete local therapy and be neurologically stable (with no requirement for an increasing dose of corticosteroids or use of anticonvulsants) for 7 days prior to enrollment.
•5. History of allergic reactions attributed to other ALK inhibitors
•6. History of interstitial pneumonitis or drug-related pneumonitis
•7. Impaired gastrointestinal function that may affect oral absorption of brigatinib
•8. Patients with known active Hepatitis B or Hepatitis C (defined as having a detectable hepatitis B or C viral load)
•9. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. Physician's discretion may be exercised to determine eligibility for patients with psychiatric illness/social situations.
+1 more criteria

Locations (1)

Fox Chase Cancer Center

Philadelphia, Pennsylvania, United States

Key Dates

Start Date

December 6, 2018

Primary Completion Date

March 18, 2020

Completion Date

June 16, 2020

Last Updated

January 5, 2021

Conditions

Anaplastic Large Cell Lymphoma, ALK-Positive

Interventions

Brigatinib

DRUG

Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors

NCT04925609

Anaplastic Large Cell Lymphoma, ALK-PositiveInflammatory Myofibroblastic Tumor+1 more

View study

ACTIVE_NOT_RECRUITINGPHASE2

Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL

NCT07013565

Anaplastic Large Cell Lymphoma, ALK-Positive

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 5, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma

Inclusion Criteria

Exclusion Criteria

Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors

Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas